AI Analysis
AI-generated analysis. Always verify with the original filing.
Enanta Pharmaceuticals, Inc. disclosed that on March 20, 2026, the United States Court of Appeals for the Federal Circuit scheduled oral argument for May 11, 2026, in the Company's appeal filed on February 3, 2025, against Pfizer Inc. for infringement of U.S. Patent No. 11,358,953 related to Paxlovid™.
Key Takeaways
1Company filed notice of appeal on February 3, 2025, with Federal Circuit against Pfizer Inc.
2Appeal seeks damages for infringement of U.S. Patent No. 11,358,953.
3Infringement relates to manufacture, use, and sale of Pfizer’s COVID-19 antiviral Paxlovid™ (nirmatrelvir tablets; ritonavir tablets).
4Federal Circuit scheduled oral argument for May 11, 2026.
5Scheduling occurred on March 20, 2026.